EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome

Enrico Carmina iD, Rosa Alba Longo

Journal of Clinical Medicine · 02.07.2026 · 15 (13) · 5165

DOI: 10.3390/jcm15135165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.07.2026. Verfasst von Enrico Carmina und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Palermo, 90139 Palermo, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Irregular menses and chronic anovulation are key components of Polyendocrine Metabolic Ovarian Syndrome (PMOS), but available treatments generally only mask the clinical problem, which presents itself again when the drugs are stopped. Because reduction of body weight in these patients is often associated with improvement of menstrual cycles, we evaluated the effects of treatment with semaglutide, a GLP-1 agonist that has emerged as an effective treatment for obesity.

Methods

A total of 96 women with PMOS and body mass index (BMI) > 25 kg/m2 completed a six-month treatment protocol with semaglutide using an individualized dose-escalation regimen. Body weight, fasting glucose, insulin levels, insulin resistance (HOMA-IR), and ovulatory function were assessed before and after treatment.

Results

After six months of treatment, mean body weight decreased significantly (−11.3 ± 5%, p < 0.01). Before treatment, 83% of PMOS patients presented with oligomenorrhea and anovulatory cycles. Following treatment, ovulatory cycles were observed in 52.5% of previously anovulatory women. The results were particularly good in overweight patients, with almost 95% of these PMOS patients achieving menstrual cycle normalization and ovulation, but also in patients with mild obesity. Results were less favorable in PMOS patients with moderate or severe obesity, but 25% of these patients achieved menstrual ovulatory cycle normalization when treated with semaglutide.

Conclusions

This study represents an important therapeutic advancement, suggesting that women with PMOS and excessive body weight should be considered for treatment with GLP-1 receptor agonists before proceeding to therapies specifically aimed at inducing normal cycles and ovulation.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 agonist treatment of PMOSGLP-1 agonistsPCOSPMOSchronic anovulation in PMOSirregular mensesobese PMOSsemaglutide

Autor:innen und Institutionen

  • School of Medicine, University of Palermo, 90139 Palermo, Italy.
  • Endocrinology Unit, FB Medical Center, 20121 Milano, Italy.

ORCID-Profile: Enrico Carmina

Zitieren

APA

Carmina, E., & Longo, R. A. (2026). Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. Journal of Clinical Medicine, 15(13), 5165. https://doi.org/10.3390/jcm15135165

Vancouver

Carmina E, Longo RA. Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. Journal of Clinical Medicine. 2026;15(13):5165. doi:10.3390/jcm15135165

BibTeX
@article{Carmina2026,
  author = {Carmina, Enrico and Longo, Rosa Alba},
  title = {Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5165},
  doi = {10.3390/jcm15135165}
}
Kostenlos starten →